Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - alendronate sodium,calcium carbonate,colecalciferol,microcrystalline cellulose -

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - alendronate sodium,colecalciferol -

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - colecalciferol, quantity: 140 microgram; alendronate sodium, quantity: 91.37 mg - tablet - excipient ingredients: magnesium stearate; microcrystalline cellulose; colloidal anhydrous silica; mannitol; hypromellose; butylated hydroxytoluene - alendronate plus d 70 mg/70 ?g and alendronate plus d 70 mg/140 ?g tablets are indicated for the treatment of:,osteoporosis in select patients where vitamin d supplementation is recommended.,prior to treatment, osteroporosis must be confirmed by:,the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by,the presence of osteoporotic fracture

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - alendronate sodium,colecalciferol -

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - colecalciferol, quantity: 70 microgram; alendronate sodium, quantity: 91.37 mg - tablet - excipient ingredients: magnesium stearate; colloidal anhydrous silica; microcrystalline cellulose; mannitol; butylated hydroxytoluene; hypromellose - alendronate plus d 70 mg/70 ?g and alendronate plus d 70 mg/140 ?g tablets are indicated for the treatment of:,osteoporosis in select patients where vitamin d supplementation is recommended.,prior to treatment, osteroporosis must be confirmed by:,the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by,the presence of osteoporotic fracture

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - colecalciferol, quantity: 140 microgram; alendronate sodium, quantity: 91.37 mg - tablet - excipient ingredients: mannitol; microcrystalline cellulose; colloidal anhydrous silica; magnesium stearate; hypromellose; butylated hydroxytoluene - alendronate plus d 70 mg/70 ?g and alendronate plus d 70 mg/140 ?g tablets are indicated for the treatment of:,osteoporosis in select patients where vitamin d supplementation is recommended.,prior to treatment, osteroporosis must be confirmed by:,the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by,the presence of osteoporotic fracture

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - colecalciferol, quantity: 70 microgram; alendronate sodium, quantity: 91.37 mg - tablet - excipient ingredients: microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; mannitol; butylated hydroxytoluene; hypromellose - alendronate plus d 70 mg/70 ?g and alendronate plus d 70 mg/140 ?g tablets are indicated for the treatment of:,osteoporosis in select patients where vitamin d supplementation is recommended.,prior to treatment, osteroporosis must be confirmed by:,the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by,the presence of osteoporotic fracture

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - alendronate sodium, quantity: 91.37 mg (equivalent: alendronic acid, qty 70 mg); colecalciferol, quantity: 0.07 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; croscarmellose sodium; colloidal anhydrous silica; povidone; magnesium stearate; butylated hydroxytoluene; gelatin; medium chain triglycerides; sucrose - tradenames are indicated for the treatment of: ? osteoporosis* in select patients where vitamin d supplementation is recommended,* prior to treatment, osteoporosis must be confirmed by: - the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by - the presence of osteoporotic fracture

Australia - English - Department of Health (Therapeutic Goods Administration)

dr reddys laboratories australia pty ltd - alendronate sodium, quantity: 91.37 mg (equivalent: alendronic acid, qty 70 mg); colecalciferol, quantity: 0.14 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; sucrose; gelatin; magnesium stearate; colloidal anhydrous silica; croscarmellose sodium; butylated hydroxytoluene; povidone; medium chain triglycerides - tradenames are indicated for the treatment of: ? osteoporosis* in select patients where vitamin d supplementation is recommended,* prior to treatment, osteoporosis must be confirmed by: - the finding of low bone mass of at least 2 standard deviations below the gender specific mean for young adults or by - the presence of osteoporotic fracture

United States - English - NLM (National Library of Medicine)

meda pharmaceuticals - cholecalciferol (unii: 1c6v77qf41) (cholecalciferol - unii:1c6v77qf41) - cholecalciferol 400 [iu]